Raloxifene hydrochloride

American Journal of Health-System Pharmacy

Volumn 57, Issue 18, 2000, Pages 1669-1678

  Snyder, K R ^a   Sparano, N ^a   Malinowski, J M ^a  

^a WILKES UNIVERSITY   (United States)

Author keywords

Breast neoplasms; Dosage; Estrogen agonist antagonists; Mechanism of action; Metabolism; Osteoporosis; Pharmacokinetics; Raloxifene hydrochloride; Toxicity

Indexed keywords

AMPICILLIN; COLESTYRAMINE; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL; WARFARIN;

BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG GLUCURONIDATION; HORMONE RECEPTOR INTERACTION; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; LEG CRAMP; LIPID BLOOD LEVEL; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0034666239     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.18.1669     Document Type: Review

References (27)

1. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
2. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
3. Selective estrogen receptor modulators
4. What do we know and what don't we know about tamoxifen in the human uterus
5. Clinical uses of antiestrogens
6. Molecular determinants of tissue selectivity in estrogen receptor modulators
7. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
8. Molecular basis of agonism and antagonism in the oestrogen receptor
9. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
10. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
11. ERb: Identification and characterization of a novel human estrogen receptor
12. Differential ligand activation of estrogen receptors ERa and ERb at AP1 sites
13. Non-genomic effects of estrogens and antiestrogens
14. Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription
15. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-a1 promoter via a novel sequence
16. The disposition and metabolism of 14C-labeled raloxifene in humans
17. Pharmacokinetics of raloxifene in men and postmenopausal women volunteers
18. Raloxifene pharmacokinetics and the associated endocrine effects in premenopausal females treated during the follicular, ovulatory, and luteal phases of the menstrual cycle
19. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
20. Raloxifene and estrogen: Comparative bone-remodeling kinetics
21. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
22. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial
23. Phase II evaluation of Ly156758 in metastatic breast cancer
24. The effect of raloxifene on risk of breast cancer in postmenopausal women
25. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
26. The effect of the anti-estrogen tamoxifen in cardiovascular risk factors in normal postmenopausal women